Administering Tafasitamab, Lenalidomide, and Rituximab for Follicular Lymphoma: A Single-Institution Experience From the Phase 3 inMIND Study (SOHO 2026) - Sep 1, 2026 - Abstract #IBCL-552; Location: LEVEL 3, HALL B3; "Experience from Fred Hutch demonstrates that reduced infusion durations for tafasitamab/placebo and rituximab delivered through the described rapid infusion protocol enabled a meaningful reduction in clinic time of >2 hours after cycle 1 day 1. Limiting intervals between pretreatment procedures and infusion would further enable completion of all infusions reliably in a single day. CD: cluster of differentiation, Fred Hutch: Fred Hutchinson Cancer Center, IRR: infusion-related reaction, IV: intravenous."
Clinical • P3 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology
|
|
Jessica Zhao 1; Heather Rasmussen 1; Christina Poh 2; Danielle Janiszewski 3; Haobo Ren 3; Michael Arbushites 3; Ajay K Gopal 1,4
|